AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 282 min read$JNJ

Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?

Johnson & Johnson (JNJ) reported positive Phase 4 STAR study results for Tremfya, showing improvements in psoriatic arthritis symptoms. The company raised its 2026 sales and EPS guidance, citing strong performance in Innovative Medicine. However, JNJ faces challenges from declining Stelara sales and potential revenue replacement risks due to biologic expirations.

Original reporting
finance.yahoo.com
Published Sep 28, 2026, 10:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial results provide a fresh growth catalyst, potentially improving guidance and share price.

02

Market read

First‑time disclosure of positive Phase 4 data for a major JNJ drug, likely to influence investor sentiment and sector dynamics.

03

What to watch

Potential reimbursement challenges and competition from emerging IL‑23 inhibitors.

Relevance 8/10Novelty 8/10Timing: post‑market Sep 25 release

Background

Johnson & Johnson's immunology franchise faces revenue pressure from Stelara biosimilars; Tremfya's new indication aims to broaden its market.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson announced positive Phase 4 STAR study results for Tremfya in psoriatic arthritis, a first‑time disclosure of trial data.

Expected impact

likely upward pressure as investors price in new growth potential for Tremfya.

Evidence & confidence

Phase 4 data is material, first reported, and addresses a key pipeline gap; market typically reacts positively to successful late‑stage trials.

Market effects

Sector

Strengthens the immunology/biologics sector, may lift peers with similar pipelines.

Regional

U.S. healthcare equities could see modest gains.

Global

Highlights continued innovation in biologics, relevant for global pharma investors.

Counterpoint

What could challenge this read

Stelara biosimilar erosion may outpace Tremfya uptake, limiting upside.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate.

  • drug
    Tremfya (guselkumab)

    IL‑23 inhibitor targeting psoriatic arthritis.

Read at source← All news

Related articles

SEP 29
$JNJMed

Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says

Bank of America raised its peak sales estimate for Johnson & Johnson's (JNJ) psoriasis drug Icotyde to $4.5B, up from $2.4B, and increased its price target to $278. The broker forecasts $70M in Q3 sales and $220M in 2026 sales, with limited changes to companywide 2026 sales forecasts. JNJ's earnings estimates were adjusted to reflect recent acquisitions and collaborations, with a Q3 EPS forecast of $2.53, below the consensus of $2.87.

proactiveinvestors.com2 min
SEP 29
$JNJMedAI 9/10

Johnson & Johnson Reports IMAAVY Myasthenia Gravis Data

Johnson & Johnson (JNJ) presented two-year data from its Vibrance-MG study, showing sustained benefits in adolescents with generalized myasthenia gravis (gMG) treated with IMAAVY. Improvements in daily function and muscle strength were maintained, with no new safety concerns. A separate survey indicated that 73.2% of adults who switched to IMAAVY from other treatments reported significant improvements.

grafa.com2 min
SEP 29
$JNJMedAI 8/10

Icotrokinra Shows Sustained Psoriasis Benefits at 1 Year

Johnson & Johnson's icotrokinra (Icotyde) showed sustained benefits in treating moderate-to-severe plaque psoriasis over one year, with high rates of skin clearance and symptom improvement. The FDA approved the drug in March. Results from the ICONIC-ADVANCE trials were published in the British Journal of Dermatology, showing 73%-78% of participants achieving clear or almost clear skin at week 52.

medscape.com3 min